- Home
- VRDN vs OMCL Comparison
VRDN vs OMCL Comparison
Compare VRDN & OMCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRDN
- OMCL
- Stock Information
- Founded
- VRDN 2006
- OMCL 1992
- Country
- VRDN United States
- OMCL United States
- Employees
- VRDN N/A
- OMCL N/A
- Industry
- VRDN Medical Specialities
- OMCL Computer Manufacturing
- Sector
- VRDN Health Care
- OMCL Technology
- Exchange
- VRDN Nasdaq
- OMCL Nasdaq
- Market Cap
- VRDN 1.3B
- OMCL 1.3B
- IPO Year
- VRDN N/A
- OMCL 2001
- Fundamental
- Price
- VRDN $15.67
- OMCL $29.84
- Analyst Decision
- VRDN Strong Buy
- OMCL Buy
- Analyst Count
- VRDN 11
- OMCL 6
- Target Price
- VRDN $38.50
- OMCL $44.83
- AVG Volume (30 Days)
- VRDN 728.3K
- OMCL 472.7K
- Earning Date
- VRDN 08-07-2025
- OMCL 07-31-2025
- Dividend Yield
- VRDN N/A
- OMCL N/A
- EPS Growth
- VRDN N/A
- OMCL N/A
- EPS
- VRDN N/A
- OMCL 0.45
- Revenue
- VRDN $302,000.00
- OMCL $1,135,755,000.00
- Revenue This Year
- VRDN N/A
- OMCL $3.84
- Revenue Next Year
- VRDN $17,102.33
- OMCL $4.07
- P/E Ratio
- VRDN N/A
- OMCL $65.79
- Revenue Growth
- VRDN 4.86
- OMCL 3.00
- 52 Week Low
- VRDN $9.90
- OMCL $22.66
- 52 Week High
- VRDN $27.20
- OMCL $55.75
- Technical
- Relative Strength Index (RSI)
- VRDN 61.91
- OMCL 53.19
- Support Level
- VRDN $13.84
- OMCL $28.80
- Resistance Level
- VRDN $14.85
- OMCL $30.57
- Average True Range (ATR)
- VRDN 0.82
- OMCL 0.78
- MACD
- VRDN -0.03
- OMCL 0.10
- Stochastic Oscillator
- VRDN 82.81
- OMCL 74.56
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
About OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.